Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1040105917 | 10401059 | 17 | F | 201307 | 20160629 | 20140822 | 20160630 | EXP | CA-ROCHE-1262976 | ROCHE | 75.61 | YR | F | Y | 77.00000 | KG | 20160630 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1040105917 | 10401059 | 1 | PS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 560 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 2 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 560 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 3 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 560 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 4 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 560 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 5 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 560 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 6 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 560 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 7 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 560 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 8 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B20212,B20152,B20343,B20162,B20243, | 125276 | 616 | MG | INFUSION | |||||||
| 1040105917 | 10401059 | 9 | C | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | 0 | ||||||||||||
| 1040105917 | 10401059 | 10 | C | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | Oral | 0 | 400 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1040105917 | 10401059 | 1 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1040105917 | 10401059 | HO |
| 1040105917 | 10401059 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1040105917 | 10401059 | Blood pressure increased | |
| 1040105917 | 10401059 | Blood pressure systolic increased | |
| 1040105917 | 10401059 | Herpes zoster | |
| 1040105917 | 10401059 | Joint effusion | |
| 1040105917 | 10401059 | Ligament rupture | |
| 1040105917 | 10401059 | Lower respiratory tract infection | |
| 1040105917 | 10401059 | Pain | |
| 1040105917 | 10401059 | Post procedural infection | |
| 1040105917 | 10401059 | Rheumatoid arthritis | |
| 1040105917 | 10401059 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 1040105917 | 10401059 | 1 | 20110112 | 0 | ||
| 1040105917 | 10401059 | 2 | 20141015 | 0 | ||
| 1040105917 | 10401059 | 3 | 20140918 | 0 | ||
| 1040105917 | 10401059 | 4 | 20140820 | 0 | ||
| 1040105917 | 10401059 | 5 | 20141112 | 0 | ||
| 1040105917 | 10401059 | 6 | 20150211 | 0 | ||
| 1040105917 | 10401059 | 7 | 20150311 | 0 | ||
| 1040105917 | 10401059 | 8 | 20150312 | 0 |